③上海莱士(002252)："SR604注射液"新增用于血管性血友病患者出血发作的预防治疗获得药物临床试 验批准通知书。 ④英力股份：公司发行股份及支付现金购买深圳市优特利能源股份有限公司77.94%股份并募集配套资 金的申请文件获得深交所受理。 格隆汇11月5日｜①天益医疗：公司产品获得欧盟MDR认证，认证产品为体外循环血路、喂食注射器、 带ENFit接头的喂食注射器、动静脉穿刺器。公司上述产品原本已获得欧盟MDD认证，此次获得欧盟 MDR认证，表明其符合欧盟最新医疗器械法规要求，具备欧盟市场的最新准入条件，可以持续在相关 海外市场合法销售。 ②创源股份：聘任叶晋盛为公司总裁。 ...

①天益医疗：公司产品获得欧盟MDR认证，认证产品为体外循环血路、喂食注射器、带ENFit接头的喂 食注射器、动静脉穿刺器。公司上述产品原本已获得欧盟MDD认证，此次获得欧盟MDR认证，表明其 符合欧盟最新医疗器械法规要求，具备欧盟市场的最新准入条件，可以持续在相关海外市场合法销售。 ②创源股份：聘任叶晋盛为公司总裁。③上海莱士："SR604注射液"新增用于血管性血友病患者出血发 作的预防治疗获得药物临床试验批准通知书。④英力股份：公司发行股份及支付现金购买深圳市优特利 能源股份有限公司77.94%股份并募集配套资金的申请文件获得深交所受理。 ...

Group 1: Financial Performance - In 2024, the company achieved a revenue of 418.96 million CNY, representing a year-on-year growth of 9.98% [3] - The net profit for 2024 was -0.744 million CNY, indicating a loss compared to the previous year [3] - The company plans to distribute cash dividends of 5.00 CNY per 10 shares, totaling approximately 28.76 million CNY, despite the negative net profit [8] Group 2: Cost and Expense Management - Management expenses increased by 45.39% and sales expenses rose by 31.25% in 2024 due to rapid growth in personnel [3] - R&D expenses surged by 94.47%, reflecting the company's commitment to innovation and development [6] Group 3: Market and Business Strategy - The company has a foreign sales ratio of approximately 38%, with no significant impact from current tariff policies on completed orders [2] - The construction of the Thailand factory is progressing as planned, with an expected operational start in 2026 [3] - The company is focusing on expanding its market presence both domestically and internationally, particularly in South America [5] Group 4: Product Development and Innovation - The company is actively developing new products, including dialysis solutions and CRRT products, to enhance its product portfolio [4] - The company has acquired CRRT business assets and plans to complete a comprehensive business ecosystem within three years [4] Group 5: Industry Outlook - The medical device industry, particularly in blood purification, is expected to grow due to increasing global end-stage renal disease patients and supportive national policies [6] - The company remains optimistic about the future of the industry, citing the essential nature of its products and the relatively low impact of market fluctuations [6]